Eli Lilly shares slipped to $1,245.40 Monday afternoon after charging toward their 52-week high, as investors took profits on the pharmaceutical heavyweight behind Mounjaro and Zepbound. Second-quarter revenue exploded 48% to $23 billion, with Mounjaro sales nearly doubling to $9.94 billion and Zepbound jumping 46% to $4.93 billion. Lilly raised its full-year revenue forecast to between $85 billion and $87 billion. The stock trades 17.97% below its GF Value estimate of roughly $1,520, signaling potential upside, though Mounjaro and Zepbound now generate nearly two-thirds of companywide sales.
Eli Lilly and CompanyShares slipped as investors took profits despite strong earnings and raised guidance.
Exxon Mobil Corp